Edition:
United Kingdom

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

38.00SEK
12 Nov 2018
Change (% chg)

-0.35kr (-0.91%)
Prev Close
38.35kr
Open
38.40kr
Day's High
38.65kr
Day's Low
37.95kr
Volume
1,196,588
Avg. Vol
1,128,389
52-wk High
39.40kr
52-wk Low
25.25kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)

Overall

Beta: 0.50
Market Cap(Mil.): kr6,302.16
Shares Outstanding(Mil.): 164.33
Dividend: 0.28
Yield (%): 0.74

Financials

  KARO.ST Industry Sector
P/E (TTM): 9.08 81.01 29.57
EPS (TTM): 4.23 -- --
ROI: 16.11 -0.53 12.77
ROE: 25.17 -3.22 14.47

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

29 Oct 2018

Private equity firm EQT launches $654 million cash bid for Sweden's Karo Pharma

STOCKHOLM Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

29 Oct 2018

Private equity firm EQT launches $654 million cash bid for Sweden's Karo Pharma

STOCKHOLM Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown (509.52 million pounds)cash bid to buy Swedish speciality pharma group Karo Pharma .

29 Oct 2018

Private equity firm EQT launches $654 mln cash bid for Sweden's Karo Pharma

STOCKHOLM, Oct 29 Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

29 Oct 2018

Earnings vs. Estimates